Evaluation of outcome measures for myasthenia gravis subgroups

•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term fol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical neuroscience 2021-09, Vol.91, p.270-275
Hauptverfasser: Luo, Yien, Dong, Xiaohua, Peng, Yuyao, Cui, Biqi, Yan, Chengkai, Jin, Wanlin, Li, Yi, Zhou, Ran, Huang, Kun, Yang, Huan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 275
container_issue
container_start_page 270
container_title Journal of clinical neuroscience
container_volume 91
creator Luo, Yien
Dong, Xiaohua
Peng, Yuyao
Cui, Biqi
Yan, Chengkai
Jin, Wanlin
Li, Yi
Zhou, Ran
Huang, Kun
Yang, Huan
description •Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups. We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes. 872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL. Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.
doi_str_mv 10.1016/j.jocn.2021.07.020
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000683571000003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0967586821003702</els_id><sourcerecordid>2560057390</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</originalsourceid><addsrcrecordid>eNqNkF1L7DAQhoMoun78Aa96KUh7JpmmbUAEWdRzQDg3eh2y6VSzbJs1aVf892Zd8VKcmxeG9xmGh7FzDgUHXv1ZFktvh0KA4AXUBQjYYzMuUeSikrjPZqCqOpdN1Ryx4xiXAKBKhEN2hCXWCKhm7Pp2Y1aTGZ0fMt9lfhqt7ynrycQpUMw6H7L-3cTxhQZnsudgNi5mcVo8Bz-t4yk76Mwq0tlXnrCnu9vH-d_84f_9v_nNQ24RccyVlRUiNGSkaWxjlKJWpCW1alGSUYRd11Jpy7I0rZKilrbtiLcNp0VKwhN2sbu7Dv51ojjq3kVLq5UZyE9RC1kByBoVpKrYVW3wMQbq9Dq43oR3zUFvveml3nrTW28aap28JehyB73RwnfROhosfYNJXNWgrDlsB1O7-X177sZPvXM_DWNCr3YoJVsbR0F_4a0LZEfdevfTnx9TP5cK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2560057390</pqid></control><display><type>article</type><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Access via ScienceDirect (Elsevier)</source><creator>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</creator><creatorcontrib>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</creatorcontrib><description>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups. We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes. 872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL. Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</description><identifier>ISSN: 0967-5868</identifier><identifier>EISSN: 1532-2653</identifier><identifier>DOI: 10.1016/j.jocn.2021.07.020</identifier><identifier>PMID: 34373039</identifier><language>eng</language><publisher>OXFORD: Elsevier Ltd</publisher><subject>Clinical Neurology ; Life Sciences &amp; Biomedicine ; MG-ADL ; MG-QOL15r ; MGC ; Myasthenia gravis ; Neurosciences ; Neurosciences &amp; Neurology ; Outcome measure ; QMG ; Science &amp; Technology</subject><ispartof>Journal of clinical neuroscience, 2021-09, Vol.91, p.270-275</ispartof><rights>2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000683571000003</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</citedby><cites>FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</cites><orcidid>0000-0002-8690-2544</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jocn.2021.07.020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,39265,46002</link.rule.ids></links><search><creatorcontrib>Luo, Yien</creatorcontrib><creatorcontrib>Dong, Xiaohua</creatorcontrib><creatorcontrib>Peng, Yuyao</creatorcontrib><creatorcontrib>Cui, Biqi</creatorcontrib><creatorcontrib>Yan, Chengkai</creatorcontrib><creatorcontrib>Jin, Wanlin</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhou, Ran</creatorcontrib><creatorcontrib>Huang, Kun</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><title>Journal of clinical neuroscience</title><addtitle>J CLIN NEUROSCI</addtitle><description>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups. We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes. 872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL. Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</description><subject>Clinical Neurology</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>MG-ADL</subject><subject>MG-QOL15r</subject><subject>MGC</subject><subject>Myasthenia gravis</subject><subject>Neurosciences</subject><subject>Neurosciences &amp; Neurology</subject><subject>Outcome measure</subject><subject>QMG</subject><subject>Science &amp; Technology</subject><issn>0967-5868</issn><issn>1532-2653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkF1L7DAQhoMoun78Aa96KUh7JpmmbUAEWdRzQDg3eh2y6VSzbJs1aVf892Zd8VKcmxeG9xmGh7FzDgUHXv1ZFktvh0KA4AXUBQjYYzMuUeSikrjPZqCqOpdN1Ryx4xiXAKBKhEN2hCXWCKhm7Pp2Y1aTGZ0fMt9lfhqt7ynrycQpUMw6H7L-3cTxhQZnsudgNi5mcVo8Bz-t4yk76Mwq0tlXnrCnu9vH-d_84f_9v_nNQ24RccyVlRUiNGSkaWxjlKJWpCW1alGSUYRd11Jpy7I0rZKilrbtiLcNp0VKwhN2sbu7Dv51ojjq3kVLq5UZyE9RC1kByBoVpKrYVW3wMQbq9Dq43oR3zUFvveml3nrTW28aap28JehyB73RwnfROhosfYNJXNWgrDlsB1O7-X177sZPvXM_DWNCr3YoJVsbR0F_4a0LZEfdevfTnx9TP5cK</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Luo, Yien</creator><creator>Dong, Xiaohua</creator><creator>Peng, Yuyao</creator><creator>Cui, Biqi</creator><creator>Yan, Chengkai</creator><creator>Jin, Wanlin</creator><creator>Li, Yi</creator><creator>Zhou, Ran</creator><creator>Huang, Kun</creator><creator>Yang, Huan</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8690-2544</orcidid></search><sort><creationdate>202109</creationdate><title>Evaluation of outcome measures for myasthenia gravis subgroups</title><author>Luo, Yien ; Dong, Xiaohua ; Peng, Yuyao ; Cui, Biqi ; Yan, Chengkai ; Jin, Wanlin ; Li, Yi ; Zhou, Ran ; Huang, Kun ; Yang, Huan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-9c563308ea5a8c8a99ed29c5ed9b4ea9e3ffde4c444ad95275cdfe1d81ebfe1e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Neurology</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>MG-ADL</topic><topic>MG-QOL15r</topic><topic>MGC</topic><topic>Myasthenia gravis</topic><topic>Neurosciences</topic><topic>Neurosciences &amp; Neurology</topic><topic>Outcome measure</topic><topic>QMG</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, Yien</creatorcontrib><creatorcontrib>Dong, Xiaohua</creatorcontrib><creatorcontrib>Peng, Yuyao</creatorcontrib><creatorcontrib>Cui, Biqi</creatorcontrib><creatorcontrib>Yan, Chengkai</creatorcontrib><creatorcontrib>Jin, Wanlin</creatorcontrib><creatorcontrib>Li, Yi</creatorcontrib><creatorcontrib>Zhou, Ran</creatorcontrib><creatorcontrib>Huang, Kun</creatorcontrib><creatorcontrib>Yang, Huan</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Yien</au><au>Dong, Xiaohua</au><au>Peng, Yuyao</au><au>Cui, Biqi</au><au>Yan, Chengkai</au><au>Jin, Wanlin</au><au>Li, Yi</au><au>Zhou, Ran</au><au>Huang, Kun</au><au>Yang, Huan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of outcome measures for myasthenia gravis subgroups</atitle><jtitle>Journal of clinical neuroscience</jtitle><stitle>J CLIN NEUROSCI</stitle><date>2021-09</date><risdate>2021</risdate><volume>91</volume><spage>270</spage><epage>275</epage><pages>270-275</pages><issn>0967-5868</issn><eissn>1532-2653</eissn><abstract>•Consistency evaluation of myasthenia gravis specific scales QMG, MG-ADL, MG-QOL15r and MGC.•Exploration of effect of clinical variables have on myasthenia gravis scales.•Comparison of the scale response to disease change in different myasthenia gravis subgroups. Disease evaluation and long-term follow-up of myasthenia gravis (MG) patients rely on disease-specific measures. We evaluated four widely used MG-specific assessments, and compared the response to disease change in different MG subgroups. We used the Cronbach's α coefficient to test reliability, Pearson correlation coefficients to test construct validity, as well as one-way ANOVA and independent-sample t-tests to access discriminant validity. Analyses of similar items between QMG and MG-ADL included paired-sample t-tests and mean score comparisons. Pearson correlation coefficients were used to describe the correlation between changes of QMG, MG-ADL, MG-QOL15r and MGC. The Wilcoxon matched-pairs signed-ranks test was performed to compare the outcomes. 872 MG patients were enrolled. QMG, MG-ADL, MG-QOL15r, and MGC all exhibited high reliability. All four scales displayed good discriminant validity according to the MGFA classification and MGC score. MG-ADL showed significant differences between patients grouped by age and gender, and MG-QOL15r showed significant differences between patients grouped by age. Analyses of similar items showed that MG-ADL achieved higher scores in bulbar items, whereas QMG produced higher scores in limb items. For patients in remission or minimal manifestation status, QMG exhibited significantly greater improvement than MG-QOL15r. In patients of MGFA I, II, III, and IV, QMG showed significantly greater improvement than MG-ADL. Patient-reported scale is an important supplement for a given period. MG-ADL has a better response to severe disease, and MG-QOL15r is more comprehensive for patients in remission or minimal manifestation status.</abstract><cop>OXFORD</cop><pub>Elsevier Ltd</pub><pmid>34373039</pmid><doi>10.1016/j.jocn.2021.07.020</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8690-2544</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0967-5868
ispartof Journal of clinical neuroscience, 2021-09, Vol.91, p.270-275
issn 0967-5868
1532-2653
language eng
recordid cdi_webofscience_primary_000683571000003
source Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Access via ScienceDirect (Elsevier)
subjects Clinical Neurology
Life Sciences & Biomedicine
MG-ADL
MG-QOL15r
MGC
Myasthenia gravis
Neurosciences
Neurosciences & Neurology
Outcome measure
QMG
Science & Technology
title Evaluation of outcome measures for myasthenia gravis subgroups
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T22%3A31%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20outcome%20measures%20for%20myasthenia%20gravis%20subgroups&rft.jtitle=Journal%20of%20clinical%20neuroscience&rft.au=Luo,%20Yien&rft.date=2021-09&rft.volume=91&rft.spage=270&rft.epage=275&rft.pages=270-275&rft.issn=0967-5868&rft.eissn=1532-2653&rft_id=info:doi/10.1016/j.jocn.2021.07.020&rft_dat=%3Cproquest_webof%3E2560057390%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2560057390&rft_id=info:pmid/34373039&rft_els_id=S0967586821003702&rfr_iscdi=true